Why the study?
Recent data suggested women have a survival benefit at 1-year follow-up after TAVR, but long-term gender-based TAVR outcomes were lacking.
Does female gender affect long-term mortality and readmissions in patients undergoing TAVR?
Does female gender affect long-term mortality and readmissions in patients undergoing TAVR?
After risk adjustment, female gender is not associated with a significant difference in long-term survival or hospital readmissions following TAVR.
Answers are grounded in this paper and cite their sources.
3-year gender-specific TAVR outcomes remain uncertain; leaves open whether 1-year female survival benefit extends to 3 years.
Objective Recent data have suggested that women have a survival benefit at 1-year follow-up. However, long-term gender-based TAVR outcomes are lacking. Methods All patients undergoing isolated TAVR from 2011 to 2017 were included. Patients were stratified by gender. The primary outcomes of the study were 3-year mortality and 3-year hospital readmissions. Multivariable logistic regression analysis was used to evaluate the risk-adjusted impact of gender on TAVR outcomes. Results A total of 1,036 patients were divided into male ( n = 518) and female ( n = 518) cohorts. Women had a borderline significantly increased STS PROM (8.3% ± 5 vs. 7.7% ± 4.4; P = 0.05). The majority of procedures were performed under conscious sedation (male: 89% vs. female: 88%; P = 0.62) and via transfemoral access (male: 81.8% vs. female: 81.4%; P = 0.46). There was no difference in operative (30-day) mortality (male: 15 [3.3%] vs. female: 17 [3.7%]; P = 0.77) or 30-day readmissions (male: 40 [10.8%] vs. female: 44 [12.2%]; P = 0.56). Perioperative blood product usage was higher for women (male: 8.1% vs. female: 14.1%; P = 0.002). There was no significant difference in major vascular complications (male: 0.4% vs. female: 1.0%; P = 0.26) or major bleeding (male: 0.2% vs. female: 0.4%; P = 0.56). Permanent pacemaker placement was higher for males (11.6% vs. 7.0%; P = 0.01). On risk-adjusted multivariable analysis, gender was not a factor associated with mortality (HR 0.99 [0.76 to 1.30]; P = 0.99) or readmission (HR 0.90 [0.72 to 1.14]; P = 0.42) at 5 years. Conclusions There was no difference in survival or readmissions on multivariable analysis for women undergoing TAVR at 3 years. Longitudinal multi-institutional data will be important to validate these findings.
No takes yet. Share an insight, caveat, or question.
Kilic et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: